In vitro activity and beta-lactamase stability of LY163892.
Susceptibility testing of clinical isolates of several gram-negative and gram-positive species showed LY163892 to be more active than cefaclor and cephalexin. OXA-2, TEM-1, TEM-2, PSE-1, CEP-1, CARB-3 and SHV-1 beta-lactamases showed similar activity against LY163892 and cefaclor, whereas OXA-1 hydrolyzed the latter more rapidly. Organisms producing these beta-lactamases, but not TEM-2 and CEP-1, appeared to be more susceptible to LY163892 than cephalexin, although cephalexin proved to be more resistant to beta-lactamase activity. Strains producing TEM-2 and CEP-1 were resistant to LY163892, cefaclor and cephalexin.
D000284:Administration, Oral; D001419:Bacteria / Q000187:drug effects* / Q000201:enzymology; D002433:Cefaclor / Q000378:metabolism / Q000494:pharmacology; D002439:Cefotaxime / Q000378:metabolism / Q000494:pharmacology; D002506:Cephalexin / Q000378:metabolism / Q000494:pharmacology; D002511:Cephalosporins / Q000008:administration & dosage / Q000378:metabolism / Q000494:pharmacology*; D004795:Enzyme Stability; D001618:beta-Lactamases / Q000378:metabolism*
D002511:Cephalosporins; C054920:loracarbef; D002433:Cefaclor; D001618:beta-Lactamases; D002439:Cefotaxime; D002506:Cephalexin